debate: will novel-agent based combination therapy become standard of care for cll? - no
Published 6 years ago • 611 plays • Length 15:02Download video MP4
Download video MP3
Similar videos
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
24:17
combination of novel agents in cll: is this the final answer?
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
12:34
debate: is it appropriate to treat patients with cll earlier in the era of novel agents? - no
-
14:21
debate: which is the optimal approach for cll? - fcr
-
13:19
ighv and tp53 sequencing: clinical utility in chronic lymphocytic leukemia (cll)
-
13:49
roger talks about living with cll
-
47:49
cll live 2015 - dr. michael keating, 'american perspective on cll'
-
16:24
chemotherapy vs novel agents in young cll patients: is there still a role for chemo?
-
19:14
debate: best approach for multiple relapsed cll after chemoimmunotherapy - other novel agents
-
14:02
debate: best frontline regimen for a cll patient aged 60 who requires therapy - fcr
-
18:49
use of novel prognostic markers in practice for cll
-
15:16
debate: how should patients with abc type dlbcl be treated today? - r-chop
-
27:18
novel treatment options in cll
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
4:42
advances in frontline therapy for cll
-
1:13
treatment challenges for young cll patients
-
0:35
novel agents could chemoimmunotherapy in chronic lymphocytic leukemia
-
12:53
selecting first-line treatment for chronic lymphocytic leukemia (cll)
-
20:21
novel agents in elderly cll patients: should the approach be different?
-
1:23
towards new combination therapies for the treatment of chronic lymphocytic leukemia
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib